HCPCS Level II code J7328 covers hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg, a viscosupplementation product used in joint management. Nationally, this code identifies a specific injectable biologic administered directly into joint spaces, relevant for orthopedic, rheumatology, and pain-management billing. Accurate coding affects clinical documentation, claims processing, and appropriate benefit determination for patients receiving intra-articular hyaluronan therapies.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes payer coverage patterns, reimbursement benchmarks, permitted settings of care, and typical claim administration for intra-articular hyaluronan products using this HCPCS Level II identifier.

Readers will learn what J7328 represents clinically, where the service is typically delivered, and how payers commonly approach coverage and payment for hyaluronan injections. The piece also reviews relevant billing considerations such as unit reporting, common modifiers, and how this code fits into broader clinical workflows. Policy updates and national reimbursement context are summarized to provide actionable intelligence for revenue cycle, clinical coding, and compliance teams.